Drug Profile


Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF 5993 pMDI; CHF-5993; Trimbow

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 24 Jul 2017 Registered for Chronic obstructive pulmonary disease in Liechtenstein, Iceland, Norway, and European Union (Inhalation)
  • 10 Jul 2017 Chiesi completes a phase III trial in Chronic obstructive pulmonary disease in Hungary, Italy, Portugal, Austria, Norway, Croatia, Poland, Denmark, Germany, Latvia and Czech Republic (Inhalation) (NCT02579850)
  • 20 May 2017 Committee for Medicinal Products for Human Use (CHMP) recommends approval of beclometasone/formoterol/glycopyrrolate for chronic obstructive pulmonary disease in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top